Scleroderma Diagnostics and Therapeutics Market Scleroderma Diagnostics and Therapeutics Market - | Page 3

A detailed qualitative analysis of factors responsible for driving and restraining market growth and
opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn
for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from
2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related
factors such as new drug launches, drugs in the pipeline, industry-institute collaborations in research
for finding a pertinent cure, and historical year-on-year growth have been taken into consideration
while estimating the market size. Growth rates for each segment within the global scleroderma
diagnostics and therapeutics market have been determined after a thorough analysis of past trends,
demographics, future trends, technological developments, clinical trials, and regulatory requirements.
These factors would help the market players to take strategic decisions in order to strengthen their
positions and expand their share in the global market.
Global Scleroderma Diagnostics and Therapeutics Market: Segmentation
Based on indication, the global scleroderma diagnostics and therapeutics market has been segmented
into localized and systemic scleroderma. Localized scleroderma affects only the skin, and in certain
patients, the underlying muscle, however, systemic scleroderma (also known as systemic sclerosis)
is much severe and affects the internal organs as well.
The major drug classes for treatment of scleroderma include Corticosteroids, Immunosuppressive
Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating
Agents, Prostacyclin Analogues, and Others. The others segment includes the drug classes of
analgesics, proton pump inhibitors, prokinetic agents, H2 blockers and ACE inhibitors etc. which are
used in symptomatic relief to the patient. Immunosuppressive agents and low dose corticosteroids are
the most commonly prescribed agents to treat scleroderma.
Based on test type, the diagnostics market has been segmented into skin biopsy, imaging techniques,
blood test, electrocardiogram and echocardiogram, and pulmonary function tests. Diagnosis of the
disease is based on physician’s assessment of patients’ medical history and clinical manifestations.
In addition, tests and procedures are undertaken to validate the clinical diagnosis and exclude
alternative diagnoses, and later for assessment of organ involvement and monitoring of disease
progression.
Global Scleroderma Diagnostics and Therapeutics Market: Geographical and Competitive
Dynamics
Geographically, the global scleroderma diagnostics and therapeutics market has been segmented into
five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition,
the regions have been further segmented by major countries for the scleroderma therapeutics market
These include the U.S., Canada, the U.K., Germany, France, China, Japan, India, Brazil, Mexico, the
UAE, and South Africa. The competition matrix section included in the report is likely to assist the
existing players to increase their market shares and new companies to establish their presence in the
radiodermatitis market.
The report also profiles major players in the scleroderma therapeutics and diagnostics market based
on various attributes such as company overview, financial overview, SWOT analysis, key business
strategies, product portfolio, and recent developments. Key companies profiled in the report include
Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc.,
Cumberland Pharmaceuticals Inc, Gilead Sciences, Inc., Pfizer, Inc., and Sanofi.
Get accurate market forecast and analysis on the Scleroderma Diagnostics and Therapeutics market.
Request a sample to stay abreast on the key trends impacting this market.